- Home
- MTG vs APLS Comparison
MTG vs APLS Comparison
Compare MTG & APLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | MTG | APLS |
|---|---|---|
| Founded | 1957 | 2009 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Property-Casualty Insurers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.9B | 5.2B |
| IPO Year | 2008 | 2015 |
Fundamental Metrics
Financial Performance| Metric | MTG | APLS |
|---|---|---|
| Price | $26.96 | $40.64 |
| Analyst Decision | Hold | Hold |
| Analyst Count | 4 | 21 |
| Target Price | $28.25 | ★ $32.71 |
| AVG Volume (30 Days) | 1.6M | ★ 7.1M |
| Earning Date | 04-29-2026 | 05-06-2026 |
| Dividend Yield | ★ 2.22% | N/A |
| EPS Growth | 8.65 | ★ 112.50 |
| EPS | ★ 3.14 | 0.20 |
| Revenue | ★ $1,213,636,000.00 | $1,003,782,000.00 |
| Revenue This Year | $2.50 | N/A |
| Revenue Next Year | $1.61 | $18.21 |
| P/E Ratio | ★ $8.60 | $203.13 |
| Revenue Growth | 0.49 | ★ 28.46 |
| 52 Week Low | $21.94 | $16.10 |
| 52 Week High | $29.97 | $40.69 |
Technical Indicators
Market Signals| Indicator | MTG | APLS |
|---|---|---|
| Relative Strength Index (RSI) | 60.21 | 87.73 |
| Support Level | $25.50 | $19.38 |
| Resistance Level | $27.66 | N/A |
| Average True Range (ATR) | 0.47 | 0.52 |
| MACD | 0.12 | 2.91 |
| Stochastic Oscillator | 98.32 | 99.77 |
Price Performance
Historical ComparisonAbout MTG MGIC Investment Corporation
MGIC Investment Corp provides private mortgage insurance, other mortgage credit risk management solutions, and ancillary services. The insurance premiums that these customers pay for the protection accounts for close to majority of the company's total revenue. Investment income accounts for the remaining revenue. The company sells its insurance products in all states of the United States and in Puerto Rico. Its greatest exposure is in California, Florida, Texas, Pennsylvania, Ohio, Illinois, Virginia, North Carolina, Georgia and New York.
About APLS Apellis Pharmaceuticals Inc.
Apellis Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel therapeutic compounds to treat diseases with high unmet needs through the inhibition of the complement system, which is an integral component of the immune system, at the level of C3, the central protein in the complement cascade. Currently it has two marketed drugs that target C3, the central protein in the complement cascade: SYFOVRE (pegcetacoplan injection) and EMPAVELI (pegcetacoplan).